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Abbreviations 
 
2-AG = 2-arachidonoylglycerol 
AA = arachidonic acid 
ATP = adenosine triphosphate 
ADP = adenosine diphosphate 
BAT = brown adipose tissue 
BMP = bone morphogenic protein 
BMPR1A = bone morphogenic protein receptor 1A  
BSA = bovine serum albumin 
cAMP = cyclic adenosine monophosphate 
CHO = Chinese hamster ovary 
CHX = cyclohexamide 
cPLA2 = cytosolic phospholipase A2 
CTx = Cholera toxin 
DAG = diacylglycerol 
DAGL = diacylglycerol lipase 
EDTA = ethylenediaminetetraacetic acid 
ERK = extracellular signal-regulated kinase 
FBS = fetal bovine serum 
FCS = fetal calf serum 
GDP = guanosine diphosphate 
GEF = guanine nucleotide exchange factor  
GFP = green fluorescent protein 
GPCR = G-protein-coupled receptor 
GTP = guanosine triphosphate 
GTPase = guanosine triphosphatase  
IBMX = 3-isobutyl-1-methyl-xanthine      
IP3 = inositol-1,4,5-trisphosphate  
IPs = inositolphosphates 
MAGL = monoacylglycerol lipase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
MAPK = mitogen activated protein kinase 
Myf5 = myogenic regulatory factor 5 
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PA = phosphatidic acid  
PBS = phosphate-buffered saline 
PCA = perchloric acid 
PI3K = phosphoinositide-3-kinase  
PIs = phosphatidylinositols 
PIP2 = phosphatidyl-inositol-4,5-bisphosphate  
PIP5K = phosphatidylinositol-4-phosphate 5-kinases  
PKA = protein kinase A  
PKC = protein kinase C 
PLA2 = phospholipase A2  
PLC = phospholipase C  
PLD = phospholipase D 
PPO = prepro-orexin 
PtdBut = phosphatidylbutanol 
PTx = Pertussis toxin 
REM (sleep) = rapid eye movement (sleep) 
RGS = regulator of G-protein signalling 
SAPK = stress-activated protein kinase  
SDS-PAGE = sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
TBS = Tris-buffered saline 
TLC = thin layer chromatography 
TPA = 12-O-tetradecanoyl-phorbol-13-acetate 
TRP (channels) = transient receptor potential (channels) 
UCP1 = uncoupling protein 1  
WAT = white adipose tissue  
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1 Introduction 
 
Orexins (also known as hypocretins) were first discovered as neuropeptides in 1998 by 
two independent research groups (de Lecea et al., 1998; Sakurai et al., 1998). They are 
produced by specific neurons in the lateral region of the hypothalamus, from where 
orexin-immunoreactive fibres project to many different regions of the brain and various 
neuronal signalling systems (Peyron et al., 1998). Orexin signalling is involved in many 
different functions of the central nervous system, including regulation of sleep and 
wakefulness, appetite and metabolism, reward and addiction, stress response, and 
analgesia. In addition it may have roles in the periphery of the body (reviewed in 
Kukkonen, 2013). Orexin receptors are G-protein coupled receptors (GPCRs) and 
signalling through them has the possibility to initiate a wide range of cellular responses. 
The receptors couple to a number of different proteins which regulate phospholipases 
and kinases, among other things, generating short term effects such as neuronal 
excitation, second messenger generation, and kinase signalling cascades, and long term 
effects such as synaptic plasticity and cell death or survival (reviewed Kukkonen, 2013). 
The cell or tissue type can therefore be of great importance in determining the response. 
Thus while many of the initial studies on orexin signalling have been done in 
recombinant expression systems, it is now crucial to study these signalling pathways in 
specific natural systems.  
 
1.1 Orexin Peptides 
 
There are two native orexin peptides, orexin-A and orexin-B, both of which are derived 
from the cleavage of the precursor molecule prepro-orexin (PPO) (de Lecea et al., 1998; 
Sakurai et al., 1998). One copy of each peptide is encoded in the PPO gene (de Lecea et 
al., 1998; Sakurai et al., 1998). Both peptides are amidated at the C-terminus and 
orexin-A also has an N-terminal glutamine cyclized to pyroglutamate and two disulfide 
bridges in its structure (Sakurai et al., 1998). The sequences of the orexin peptides are 
highly conserved in mammals. Lower vertebrates also produce orexins, however the 
sequences are less conserved (reviewed in Kukkonen, 2013). Invertebrates have not yet 
been found to produce orexins (Scammell & Winrow, 2011). Currently, no other 
neuropeptides are known to bind the orexin receptors (reviewed in Kukkonen, 2013).  
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In 1999, Kastin & Akerstrom showed that orexin-A is more stable and lipophilic than 
orexin-B, and that orexin-A is capable of crossing the blood brain barrier via simple 
diffusion. Subsequent studies however have found contradicting results, with little or no 
penetrance of orexin-A to the brain (Bingham et al., 2001; Fujiki et al., 2003).  
 
1.2 Physiological Significance of Orexins 
 
1.2.1 Regulation of Sleep and Wakefulness 
 
Orexins are necessary for the regulation of normal sleep-wake cycles and the 
maintenance of wakefulness. In both rodents and primates, orexin-producing neurons 
are active during wakeful periods and high levels of orexin-A are present. During sleep 
periods the neurons are non-active and extracellular levels of orexin-A drop by 
approximately half (Taheri et al., 2000; Zeitzer et al., 2003).  Forced wakefulness during 
time periods normally associated with sleep causes the orexin concentrations to remain 
high, suggesting a direct effect of orexin rather than being mediated through circadian 
signals (Zietzer et al., 2003). 
 
Narcolepsy is a disorder in which patients are unable to maintain proper sleep-wake 
cycles. Those suffering from this disorder can experience increased daytime urges to 
sleep, sleep attacks, cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, 
and frequent transitions between sleep and wakefulness (Tsujno & Sakurai, 2009). 
Thannical et al. (2000) showed that human narcolepsy is caused by orexin deficiency. In 
different studies using rat, mouse, and canine models, elimination of the orexinergic 
neurons or orexin/orexin receptor knockout results in narcolepsy (Chemelli et al., 1999; 
Lin et al., 1999; Gerashchenko et al., 2001; Kalogiannis et al., 2011). It is the current 
belief that human narcolepsy is caused by death of the orexinergic neurons, resulting in 
decreased orexin levels, but the mechanism of cell death has yet to be proven (reviewed 
in Kukkonen, 2013). Thus orexin agonists could potentially become a target for 
therapeutic drugs aimed at treating narcolepsy. However, small molecule agonists for 
orexin receptors remain unknown and orexin-A itself lacks the desirable properties to 
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make it a good drug, with high concentrations required to get an effect, potentially 
limited blood-brain penetrance, and suboptimal metabolism rates (Kukkonen, 2013). 
 
Conversely, orexin antagonists could prove successful as treatment for insomnia. In 
2012 Merck completed phase III clinical trials for treatment of insomnia with an orexin 
receptor antagonist, suvorexant, and the New Drug Application has been accepted for 
review by the U.S. Food and Drug Administration. If approved, suvorexant would be 
the first orexin receptor antagonist medication in clinical use 
(http://www.mercknewsroom.com/press-release/prescription-medicine-news/merck-
announces-fda-acceptance-new-drug-application-suvorex). Current treatments for 
insomnia include benzodiazepine receptor agonists (most common), sedating 
antidepressants or antipsychotics, and antihistamines. The problem is that all of these 
carry large risks for undesired side effects such as carryover of sleepiness the following 
morning, mental fog, confusion, amnesia, imbalance and falls, sleepwalking, 
hypotension, weight gain, and arrhythmias, as well as a risk of dependence and 
addiction (Scammell & Winrow, 2011). One major problem occurring with the use of 
benzodiazepine/benzodiazepine-like receptor agonists is decreased sleep quality and 
disturbed sleep architecture, for example a reduction in the time period spent in rapid 
eye movement (REM) sleep (Tsoi, 1991). REM sleep deprivation is associated with 
enhanced negative emotional reactivity, such as frustration, fear, and anxiety, and also 
with a decreased capability for concentration, decision making, and emotional 
processing and coping abilities (Rosales-Lagarde et al., 2012). Targeting the orexin 
system may produce fewer side effects since orexin more selectively promotes 
wakefulness, supported by the currently available data from the phase III suvorexant 
trials. There is also the idea that addiction and dependence risk should be lower because 
orexin antagonists also reduce drug seeking behavior, and overdose consequences 
would be less severe since orexin antagonists shouldn’t have a large effect on 
respiration or blood pressure (Scammell & Winrow, 2011). One study by Vermeeren et 
al. (2012) demonstrated that suvorexant does not impair next-day driving ability in 
healthy people under age 65, which again supports this theory of less severe side effects. 
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1.2.2 Regulation of Appetite and Metabolism 
 
As mentioned earlier, orexinergic neurons are confined to the lateral hypothalamic area 
of the brain. This region has historically proved important for feeding and energy 
homeostasis by coordinating behavioral, metabolic, and neuroendocrine responses 
(Bernardis & Bellinger, 1993; Willie et al., 2001). In response to reduction in food 
availability and intake, both animals and humans adapt by assuming a state of increased 
alertness and disruption of normal sleep patterns, which in nature would allow for better 
chances of finding food (Borbely, 1977; Danguir & Nicolaidis, 1979; Dewasmes et al., 
1989; Karklin et al., 1994). Thus appetite and sleep are inversely related, such that in 
times of hunger the animal needs to be in a state of arousal to seek out food, and when 
food is plenty then sleep may be indulged. This reasoning provides a link to the 
sleep/wake cycle regulatory functions of orexins. Another link is the association of 
obesity and narcolepsy, noted already in the 1930’s (Cave, 1931; Daniels, 1934), 
although challenged in some recent studies (reviewed in Kukkonen, 2013).  
 
The orexins were originally named as such due to the discovery that injection of orexin 
into rats leads to increased feeding behavior (Sakurai et al., 1998). Multiple studies have 
shown that after 12 days of fasting orexinergic neurons are activated and PPO mRNA 
levels increase (Sakurai et al., 1998; Yamanaka et al., 2003; Johnstone et al., 2006). The 
paradox however is that while lack of orexin decreases feeding, it also increases 
susceptibility to weight gain (Funato, 2009). In addition, ectopic expression of orexin 
yields a protective effect against weight gain on a high-calorie diet (Funato, 2009). 
Therefore the current belief is that the role of orexin lies more in metabolism regulation, 
rather than direct feeding behavior (reviewed in Kukkonen, 2013). Injection of orexin 
into the central nervous system increases metabolic rate (reviewed in Kukkonen et al., 
2002), and Sellayah et al. (2011) demonstrated that orexin-null mice are unable to raise 
their metabolic rate in response to increased caloric intake, resulting in rapid weight 
gain in mice fed a high fat diet. It should be noted however that these mice were from 
homozygous PPO-KO mothers and thus this effect could partially be explained by the 
impaired orexin-driven brown adipose tissue (BAT) development (discussed later) 
rather than the actual loss of orexin signalling; orexin-null mice from heterozygous 
PPO-KO mothers still have functional BAT thermogenesis (Zhang et al., 2010). The 
loss of orexin did not have a large effect on mice fed a low fat diet. For both diets the 
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mice lacking orexin displayed reduced food intake, confirming that the weight gain is 
not due to overconsumption. It was also demonstrated that mice of both genotypes had 
similar levels of physical activity on both diets (Sellayah et al, 2011). 
 
1.2.3 Orexins and Brown Adipose Tissue 
 
The ability to raise metabolic rate and energy expenditure in response to caloric intake 
is called diet-induced thermogenesis and acts as a mechanism to maintain energy 
balance. BAT plays an essential role in this. These cells express a unique protein, 
uncoupling protein 1 (UCP1), which allows for the uncoupling of metabolism from 
oxidative respiration and directs energy to heat production instead of adenosine 
triphosphate (ATP) production (reviewed in Cannon & Nedergaard, 2004). In rodents 
BAT is present throughout the life cycle, whereas in humans it is mainly present at birth 
and early childhood as a defense mechanism to maintain body temperature (Langin, 
2010). It was originally thought that BAT disappeared from humans within the first 
years of life, but recent evidence has shown its continued presence and activity in adults 
as well (reviewed in Nedergaard et al., 2007).  
 
Unlike other organs, adipose tissue has the ability to expand or retract to vastly different 
states, based on the organism’s energy balance and disease situation. This expansion is 
due to both an increase in size and number of the adipocytes (Algire et al., 2013). Both 
white adipose tissue (WAT) and BAT are mesodermal in origin and the progression to a 
mature adipocyte involves two phases, determination and differentiation. At the 
determination stage, pluripotent mesenchymal stem cells become committed to either 
the adipogenic or myogenic lineage, based on the expression of myogenic regulatory 
factor 5 (Myf5), to become preadipocytes (also called adipocyte progenitor cells) 
(Figure 1). The preadipocytes can then divide many times before undergoing 
differentiation into mature adipocyte cells (Algire et al., 2013). It is also possible to 
induce BAT formation from WAT lineage cells, possibly either by transdifferentiation 
of mature WAT cells or differentiation from the preadipocytes. While these cells are 
similar morphologically and functionally to regular BAT they are of different lineage, 
as seen by the expression of distinct markers (Algire et al., 2013). These have also been 
called "brite" or "beige" adipocytes.  
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Figure 1. Origin of adipocytes. Adipocytes (white, inducible brown and brown) are 
mainly derived from mesenchymal stem cells of mesodermal origin. White adipocytes 
are derived from progenitors of adipogenic lineage or hematopoietic progenitors. 
Inducible brown adipocytes differentiate directly from adipocyte progenitors or may be 
produced through transdifferentiation from white adipocytes. Whether or not these cells 
can be derived from hematopoietic progenitors is not known. Finally, brown adipocytes 
originate from progenitors of myogenic lineage. Myf, myogenic regulatory factor. 
Reprinted from Biochemica et Biophysica Acta 1831, Algire, C., Medrikova, D. & 
Herzig, S., White and brown adipose stem cells: from signaling to clinical implications, 
p898, 2013, with permission from Elsevier. 
 
 
Sellayah et al. (2011) suggested impaired BAT function as the mechanism for obesity 
associated with orexin deficiency. Without orexin present the preadipocyte cells fail to 
differentiate into mature brown adipocytes in mice. Thus orexin is necessary for 
functional BAT thermogenesis (although contradicted by results obtained by Zhang et 
al. (2010)), triglyceride storage, and proper BAT development. This is specific however 
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to BAT, as WAT development remains normal even in the absence of orexin (Sellayah 
et al., 2011). As BAT development in mice occurs during embryogenesis, the newborns’ 
phenotype may be solely dependent upon the maternal genotype, i.e. the presence or 
absence of placental orexins (Zhang et al., 2010; Sellayah et al., 2011; Kukkonen, 
2013). This is further supported by the observation that placental injection of orexin is 
capable of rescuing the phenotype to normal BAT (Sellayah et al., 2011).  
 
Traditional signalling for brown adipogenesis involves the binding of bone 
morphogenic proteins (BMPs) to bone morphogenic protein receptor 1A (BMPR1A) to 
activate a signalling cascade through Smad 1/5, and a parallel activation of p38 
mitogen-activated protein kinase (MAPK), both of which are necessary for 
differentiation into mature brown adipocytes (Hata et al., 2003; Cao et al., 2004; Tseng 
et al., 2008). Orexin acts through OX1 receptors (discussed later) to induce 
differentiation of precursor cells to brown adipocytes in a similar manner, via activation 
of both p38 MAPK and BMPR1A signalling (Sellayah et al., 2011). The suggested 
mechanism is that orexin activates phospholipase C (PLC), as has been previously 
shown (Ammoun et al., 2006; Johansson et al., 2007), which sets off a signalling 
cascade eventually leading to the phosphorylation of p38 MAPK to its active state to 
trigger adipogenesis (Sellayah et al., 2011). In parallel, orexin stimulates increased 
expression of both BMP-7 and BMPR1A mRNA and decreased expression of mRNA 
for adipogenic inhibitory factors, and signalling proceeds through Smad 1/5 
phosphorylation. Both of these pathways are necessary for differentiation of the 
precursor cells to mature adipocytes (Sellayah et al., 2011).  
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Figure 2. Model of orexin-induced differentiation. Orexin binding to orexin receptor 1 
(OXR1, OX1) induces phospholipase C (PLC) activation, which then stimulates p38 
MAPK (mitogen activated protein kinase) to activate brown-fat adipogenesis. The 
second arm of OX signalling is relayed via Smad 1/5 phosphorylation in a bone 
morphogenic protein receptor 1A (BMPR1A)-dependent manner. Both the signalling 
arms contribute to OX-dependent differentiation such that inhibition of either pathway 
impairs brown-fat differentiation. Reprinted from Cell Metabolism 14, Sellayah, D., 
Bharaj, P. & Sikder, D., Orexin is required for brown adipose tissue development, 
differentiation, and function, p487, 2011, with permission from Elsevier. 
 
 
1.3 G-Protein-Coupled Receptors 
 
GPCRs are possibly the most numerous and diverse class of receptors, and can be found 
in a wide variety of eukaryotic organisms from yeasts to invertebrates to plants and 
mammals. With more than 800 identified human GPCRs, they make up approximately 
2% of the human genome and represent the largest known gene family in humans 
(Frederiksson et al., 2003). GPCRs are involved in a huge range of biological functions 
and can be found in the systems for vision, smell, taste, neurotransmission, hormonal 
signalling, chemotaxis, cell growth, embryogenesis, and differentiation (Palczewski & 
Orban, 2013). The stimuli they respond to includes both physical and chemical entities 
17 
 
such as photons, ions and other small soluble molecules, lipids, nucleotides, peptides, 
and proteins (Frederiksson et al., 2003; Palczewski & Orban, 2013). GPCRs make good 
drug targets and it has been estimated that 30% of the current prescription drugs 
available act on GPCRs (Hopkins & Groom, 2002).  
 
GPCRs share a common structure of seven transmembrane α-helices, an N-terminal 
extracellular domain, and a C-terminal cytoplasmic domain. The name comes from their 
association with the cytoplasmic heterotrimeric G-proteins, which transmit the signal 
from the cell membrane to the intracellular environment to elicit the response. The 
minimum GPCR signalling system consists of the receptor, a G-protein, an effector 
protein, and a regulator of G-protein signalling (RGS) protein (Ross & Wilkie, 2000).  
 
Different classification systems exist for GPCRs, the major one being the AF system 
(Kolakowski, 1994), which is based on sequence similarity. Another commonly used 
way to classify GPCRs is the GRAFS system (Fredriksson et al., 2003), which is based 
on phylogenetic similarities, yielding the glutamate, rhodopsin, adhesion, 
frizzled/taste2, and secretin families.  
 
1.3.1 Orexin Receptors 
 
Orexins belong to the class A or rhodopsin-like family of GPCRs. They comprise their 
own subgroup with only about 30% homology to other GPCRs (Kukkonen et al., 2002). 
There are two orexin receptors, OX1 and OX2. OX1 binds orexin-A preferentially at up 
to 100 times over orexin-B, where as OX2 binds both orexin-A and orexin-B equally 
(Sakurai et al., 1998). Figure 3 shows the peptide sequences of the two orexin receptors 
and demonstrates the classic GPCR structure exhibited by both.  
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Figure 3. Peptide sequences for human orexin receptors OX1 and OX2. The sequences 
presented are only one of many known sequence variants/polymorphisms. Reprinted 
from American Journal of Physiology Cell Physiology 304, Kukkonen, J.P., Physiology 
of the orexinergic/hypocretinergic system: a revisit in 2012, pC5, 2013, with permission 
from The American Physiological Society. 
 
 
The orexin receptors have not been crystallized, therefore predictions for structure and 
important regions for binding affinity are based on computer models, receptor 
mutagenesis, and domain exchange mutagenesis between OX1 and OX2 (reviewed in 
Kukkonen, 2013). Two isoforms (α and β) of OX2 are expressed in mice as a result of 
alternative splicing in the C-terminal region. It’s possible the splicing regulation is 
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specific to brain nuclei or tissue type (Chen & Randeva, 2004; Chen et al., 2006). 
Multiple sequence variants can be found in humans, some of which segregate with 
disorders but causative mechanisms have yet to be described (reviewed in Kukkonen, 
2013). 
 
1.4 Cellular Signalling of Orexins 
 
The cellular responses to orexins are quite varied depending on cell type and even 
within a single cell. Orexin signalling proceeds through G-proteins as well as other 
mediators. Activation/inhibition of ion channels, kinase activation, and second 
messenger generation are among the major responses to orexins (Figure 4) (reviewed in 
Kukkonen, 2013). 
 
 
 
Figure 4. Cellular signalling responses to orexins. Abbreviations of importance: AC, 
adenylyl cyclase; PLA2, phospholipase A2; PLC, phospholipase C; PLD, phospholipase 
D; PKA, protein kinase A; PKC, protein kinase C; MAPK, mitogen activated protein 
kinase; SAPK, stress-activated protein kinase. Reprinted from American Journal of 
Physiology Cell Physiology 304, Kukkonen, J.P., Physiology of the 
orexinergic/hypocretinergic system: a revisit in 2012, pC7, 2013, with permission from 
The American Physiological Society. 
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1.4.1 G-Proteins 
 
Heterotrimeric G-proteins act as the intracellular signalling partners to GPCRs. They are 
composed of three subunits: Gα, Gβ, and Gγ. When GDP is bound to the Gα subunit 
(resting state), Gα, Gβ, and Gγ are tightly bound to each other. When a GPCR binds its 
ligand it acts as a guanine nucleotide exchange factor (GEF) and promotes the release of 
GDP from Gα, leaving it free to bind GTP. GTP-bound Gα undergoes a conformational 
change which triggers the dissociation of Gβγ (Gilman, 1987; Wall et al., 1998). Both 
Gα and Gβγ can interact with effector proteins and initiate downstream signalling 
cascades (Figure 5). Gα has intrinsic guanosine triphosphatase (GTPase) activity, which 
will eventually hydrolyze GTP to GDP. Interaction with RGS proteins can speed up this 
process (Ross & Wilkie, 2000). At this point Gα is now back to the inactive state, 
reassociation with Gβγ occurs, and any interactions with effector proteins end (Gilman, 
1987; Ford et al., 1998; Li et al., 1998). 
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Figure 5. G-Protein-Coupled Receptor (GPCR)-activated signalling through G-proteins. 
Reprinted from Plant Signaling & Behavior 4, Tuteja, N., Signaling through G protein 
coupled receptors, p943, 2009, under open access content license. 
 
 
The Gα subunits are divided into four families: Gαs, Gαi/o, Gαq, and Gα12/13 (Simon et 
al., 1991). Gαs proteins activate adenylyl cyclase and are sensitive to cholera toxin 
(Milligan et al., 1989). Gαi proteins inhibit adenylyl cyclase and are sensitive to 
pertussis toxin, with the exception of Gαz. Some members of this family are involved in 
taste, specifically bitter and sweet, and also vision (Ribeiro-Nato & Rodbell, 1989). Gαq 
proteins activate phospholipase Cβ (PLC) (Taylor et al., 1991). Gαq proteins can also 
activate monomeric G-proteins (Mizuno et al., 2009). Gα12/13 proteins possess a 
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different structure than the other Gα families and can have many functions, although a 
major one is signalling to the Rho family of GTPases (Suzuki et al., 2009). 
 
Direct measurement of receptor coupling to G-proteins is difficult due to a lack of 
specific molecular tools and the necessity of disrupting the cellular membrane, which 
may then disrupt signalling pathways. However, based on indirect measurements, there 
is evidence that both OX1 and OX2 can couple to the Gαs, Gαi/o, and Gαq families 
(reviewed in Kukkonen, 2013). 
 
1.4.2 Kinase Activation 
 
Orexin activates extracellular signal-related kinase (ERK) and p38 MAPK/stress-
activated protein kinase (SAPK) cascades in recombinant cells (Ammoun & Johansson 
et al., 2006; Ammoun & Lindholm et al., 2006) and some native cells/cell lines, for 
example in BAT precursor cells (Sellayah et al., 2011). The Ras family proteins are 
suggested as the upstream activators of ERK, most likely regulated by protein kinase C 
(PKC), phosphoinositide-3-kinase (PI3K), and Src signalling (Ammoun & Johansson et 
al., 2006). The PKCδ isoform has also been identified as a target of orexin signalling, 
possibly activated through PLCβ mediated diacylglycerol (DAG) production 
(Holmqvist et al., 2005) although this view has also been challenged (Jäntti et al., 2012). 
These kinase pathways have an influence on cell growth, plasticity, cell death/survival, 
and in the case of the BAT precursors, they seem to have importance for differentiation 
and development to mature brown adipocytes (Sellayah et al., 2011; Kukkonen, 2013). 
 
1.4.3 Influence on Ion Channels 
 
From their first discovery orexins have been known to be neuroexcitory (deLecea et al., 
1998). They employ both pre- and post- synaptic mechanisms, although the post-
synaptic depolarization has been studied in more detail. Orexin causes an inhibition of 
K
+
 channels and activation of cation influx channels, resulting in the post-synaptic 
depolarization of the neuron (reviewed in Kukkonen, 2013). In recombinant Chinese 
hamster ovary cells (CHO) orexin activates a receptor-operated Ca
2+
 influx pathway 
(Lund et al., 2000; Larsson et al., 2005; Turunen et al., 2010), which may be mediated 
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partially by transient receptor potential (TRP) channels (Larsson et al., 2005). It is still 
unclear as to the activation mechanism for the non-selective cation channels but the 
phospholipase A2 (PLA2) pathway may be involved, at least in the recombinant cells 
(Turunen et al, 2010; Turunen et al., 2012). 
 
1.4.4 Generation of Lipid Messengers 
 
Lipid messengers arise from membrane phospholipids upon hydrolysis by a 
phospholipase or phosphorylation by a lipid kinase. These signalling molecules can act 
in intracellular pathways and/or extracellular signalling, or they may be precursors to 
other signalling molecules. In addition, changes in the amount of a normal membrane 
lipid itself can be a signal (reviewed in Kukkonen, 2011).  
 
PLC hydrolyzes phosphoinositides, typically phosphatidyl-inositol-4,5-bisphosphate 
(PIP2), producing DAG and inositol-1,4,5-trisphosphate (IP3). The major target of DAG 
is activation of protein kinase C (PKC), although other proteins can also be activated by 
this messenger; DAG can also be a substrate to produce other signalling molecules 
(Turunen et al., 2012; reviewed in Kukkonen, 2011). IP3 is important for the opening of 
endoplasmic reticulum Ca
2+
 release channels and the subsequent increase of 
intracellular Ca
2+
 concentration (reviewed in Kukkonen, 2011). Studies in various 
recombinant cell systems have shown that both OX1 and OX2 receptors activate PLC 
(Lund et al., 2000; Holmqvist et al., 2002; Johansson et al., 2008; Putula & Kukkonen, 
2012). 
 
Phospholipase D (PLD) hydrolyzes phosphatidylcholine, producing choline and 
phosphatidic acid (PA). PA itself is an intracellular signalling molecule and among 
other things activates type I phosphatidylinositol-4-phosphate 5-kinases (PIP5K), 
necessary for PIP2 production (van den Bout & Divecha, 2009). Alternatively, PA can 
be converted into DAG (Brindley & Pilquil, 2009) which has many different possible 
targets, as already discussed. PLD is strongly activated by orexin in recombinant CHO-
hOX1 cells (Jäntti et al., 2012). The activation occurs through PKCδ but it does not seem 
to be linked to PLC-dependent DAG generation (Jäntti et al., 2012). Figure 6 outlines 
this pathway and the method for selective monitoring of it. 
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Figure 6. Schematic representation of signalling from orexin binding to activation of 
PLD, and selective monitoring using the butanol transphosphatidylation method (further 
described and justified under Materials and Methods). Circled item is the molecule 
measured in the assay. Other pathways have been excluded for clarity. PKC, protein 
kinase C; PLD, phospholipase D; PC, phosphatidylcholine; PA, phosphatidic acid; 
PtdBut, phosphatidylbutanol.  
 
 
Arachidonic acid (AA) and 2-arachidonoyl glycerol (2-AG) are both released upon 
orexin treatment in recombinant cells (Turunen et al., 2012). AA can be produced by 
multiple pathways, such as the action of phospholipase A2 (cPLA2) on membrane 
glycerophospholipids or PA, or the breakdown of 2-AG by monoacylglycerol lipase 
(MAGL) (Kukkonen, 2011). 2-AG is produced by mainly by the action of 
diacylglycerol lipase (DAGL) on DAG (Kukkonen, 2011). Figure 7 provides a 
graphical depiction of these pathways. 2-AG is an endocannabinoid. Endocannabinoids 
bind to the CB1 and CB2 GPCRs to regulate appetite, nociception, memory, reward, and 
mood; at the synaptic level they perform retrograde transmission, where the 
endocannabinoids produced postsynaptically act on the presynaptic inhibitory CB1 
receptors (Kano et al., 2009). There is an overlap in some of the physiological functions 
of endocannabinoids and orexins, and also in their neuroanatomical distribution 
(reviewed in Kukkonen, 2013). It has also been proposed that OX1 and CB1 receptors 
form heteromeric complexes together to increase signalling (Hilairet et al., 2003; Ellis et 
al., 2006; Ward et al., 2011).  
 
 
25 
 
 
Figure 7. Schematic representation of signalling from orexin binding to release of AA 
and 2-AG. Circled items are the molecules measured in the assay. Other pathways have 
been excluded for clarity. PKC, protein kinase C; PLD, phospholipase D; PA, 
phosphatidic acid; cPLA2, cytosolic phospholipase A2; AA, arachidonic acid; PLC, 
phospholipase C; PIs, phosphatidylinositols; IPs, inositolphosphates; DAG, 
diacylglycerol; DAGL, diacylglycerol lipase; 2-AG, 2-arachidonoyl glycerol; MAGL, 
monoacylglycerol lipase.  
 
 
1.4.5 Influence on Adenylyl Cyclase 
 
Adenylyl cyclase converts ATP to cyclic adenosine monophosphate (cAMP) (Figure 8). 
cAMP is a ubiquitous second messenger and it is involved in regulation of a wide range 
of cellular processes, including glycogen metabolism, hormone synthesis, ion channels, 
gene transcription, and activation of other enzymes, particularly protein kinase A (PKA) 
(Holmqvist et al., 2005). The adenylyl cyclase family of enzymes consists of ten 
isoforms, nine of which are membrane-bound and the other one soluble (Patel et al., 
2001). All of the membrane-bound adenylyl cyclases are regulated by G-proteins, with 
Gαs having a stimulatory effect and Gαi an inhibitory effect (Milligan et al., 1989; 
Ribeiro-Nato & Rodbell, 1989).  Adenylyl cyclase regulation is also accomplished via 
other intracellular messengers, most importantly Ca
2+
, PKC and G (reviewed in 
Hurley, 1999). The response of adenylyl cyclase to orexin appears to be complex, with 
evidence for activation from both OX1 and OX2 in recombinant cells (Holmqvist et al., 
2005; Tang et al., 2008) and native cells (Malendowicz et al., 1999; Gorojankina et al., 
2007), inhibition from OX1 in some recombinant cells (Holmqvist et al., 2005), and no 
response in some other cell types (van den Pol et al., 1998; Larsson et al., 2003; Magga 
et al., 2006). Since each isoform of adenylyl cyclase is regulated independently one 
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possibility is that these differences reflect differences in either the isoform expression 
patterns between cell lines/tissue types or the subcellular localization of isoforms 
(Ostrom et al., 2012). 
 
 
 
Figure 8. Schematic representation of signalling from orexin binding to activation or 
inhibition of adenylyl cyclase. Circled item is the molecule measured in the assay.  
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2 Research Objectives 
 
The majority of knowledge on orexin signalling cascades has been obtained from 
recombinant expression systems, due to the fact that isolating native orexin receptor-
expressing cells or cell lines has proven difficult. However, studies with natural orexin 
systems are necessary in order to test the significance for physiological responses in 
specific tissue types. With the recent discovery that orexin is capable of inducing the 
differentiation of precursor cells to brown adipocytes, two mouse cell lines were 
identified as having functional OX1 orexin receptor expression, C3H10T1/2 
mesenchymal stem cells and HIB1b preadipocytes (Sellayah et al., 2011). 
 
The goal of this project was to investigate orexin signalling in these two cell lines. The 
specific responses investigated were: p38 mitogen-activated protein kinase (MAPK) 
activation; phospholipase D (PLD) activity; arachidonic acid (AA) and 2-
arachidonoylglycerol (2-AG) release; and adenylyl cyclase activity. 
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3 Materials and Methods 
 
3.1 Cell Lines 
 
C3H10T1/2 mouse mesenchymal stem cells (Reznikoff et al., 1973) and HIB1b mouse 
brown preadipocyte cells (Ross et al., 1992) were from Dr. Devanjan Sikder (Diabetes 
and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, 
FL, USA). CHO-hOX1 Chinese hamster ovary cells expressing human OX1 receptors 
have been described earlier (Lund et al, 2000). 
 
3.2 Cell Culture  
 
C3H10T1/2 and HIB1b cells were cultured in Dulbecco’s Modified Eagle’s Medium 
DMEM with 4.5 g/L glucose without L-glutamine (Lonza, Verviers, Belgium), 
supplemented with 10% fetal calf serum (FCS), 1% penicillin + streptomycin, 10% 
glutamine, and 10 mM HEPES Buffering Solution (Gibco by Life Technologies, 
Paisley, UK). CHO-hOX1 cells were cultured in HAM’s F-12 Nutrient Mixture (Gibco), 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin + streptomycin, and 10 
mM HEPES Buffering Solution (Gibco). All cells were incubated at 37°C with 5% CO2. 
To split cells, they were first washed with phosphate buffered saline (PBS), detached 
with PBS + 0.02% (w/v) ethylenediaminetetraacetic acid (EDTA) for 34 minutes at 
37°C, centrifuged (4 min, 1500 rpm), and re-suspended in cell culture medium. 
 
3.3 p38 Western Blot Analysis 
 
Activation of p38 MAPK was assessed by Western blotting with antibodies against the 
dually phosphorylated (activated) p38 (Table 1). Cells were plated on 6-well plates 
(CellStar by Greiner Bio-One, Frickerhausen, Germany) at 150 000 cells/well in cell 
culture medium and changed to serum-free medium one day prior to the experiment.  
 
The cells were activated in serum-free medium containing the activators (Table 2) for 
10 or 30 min. After the activation medium was removed the cells were placed on ice, 
washed once with ice-cold PBS, then collected in 100 μL lysis buffer (Appendix 1) to 
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Eppendorf tubes. The samples were centrifuged (2 min, 16 000 rpm) to remove the 
insoluble fractions and the supernatants collected.  
 
The samples were separated by 10% sodium dodecyl sulfate – polyacrylamide gel 
electrophoresis (SDS-PAGE) (Appendix 1), then transferred to Hybond™-C Extra 
nitrocellulose membranes (Amersham Biosciences, Little Chalfont, Buckinghamshire, 
UK). The membranes were blocked with Odyssey Infrared Imaging System Blocking 
Buffer (LI-COR Inc., Lincoln, NE, USA):Tris-buffered saline (TBS) (Appendix 1) 
(50:50) for 1 h at room temperature. The membranes were incubated with the primary 
anti-active p38 antibody and, as the loading control, anti-total ERK antibodies (Table 1) 
overnight at +4ºC, then with the secondary antibodies (Table 1) for 1 h at room 
temperature. Odyssey Infrared Imager and software (LI-COR Inc.) was used for 
detection of the antibodies. Band mean intensities were measured with Nikon Imaging 
Software NIS-Elements AR (Version 3.1, Nikon, Tokyo, Japan) and background level 
intensity subtracted.  
 
 
Table 1. List of antibodies used in western blot analysis. 
Antibody Type Working dilution Source 
anti-ACTIVE® p38 pAb, 
Rabbit, (pTGpY) 
primary 1:1500 Promega, Madison, 
WI, USA 
anti-p44/42 MAPK 
(ERK1/2), Mouse mAb, 
(L34F12) 
primary 1:2500 Cell Signalling 
Technology, 
Boston, MA, USA 
IRDye 680RD Goat anti-
Rabbit IgG (H+L) 
secondary 1:10 000 LI-COR Inc., 
Lincoln, NE, USA 
IRDye 800CW Goat anti-
Mouse IgG (H+L) 
secondary 1:10 000 LI-COR Inc., 
Lincoln, NE, USA 
Precision Plus Protein™ 
Western C™ Standard 
size marker N/A BIO-RAD, 
Hercules, CA, USA 
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Table 2. List of drugs and chemicals used. 
Drug/Chemical Use Source 
Adenosine triphosphate 
(ATP) 
P2 receptor ligand for 
adenylyl cyclase and  
AA/2-AG assays 
Sigma-Aldrich, St. Louis, 
MO, USA 
Arachidonic acid (AA)  
 
Standard for TLC 
separation 
Cayman Europe, Tallinn, 
Estonia 
2-arachidonoylglycerol (2-
AG) 
 
Standard for TLC 
separation 
Cayman Europe, Tallinn, 
Estonia 
Cholera toxin (CTx) Gαs activator and therefore 
adenylyl cyclase stimulator 
Calbiochem, La Jolla, CA, 
USA 
Cycloheximide (CHX) Protein synthesis inhibitor 
and possible p38 MAPK 
stimulator via cell stress 
Sigma-Aldrich, St. Louis, 
MO, USA 
Forskolin Adenylyl cyclase stimulator Sigma-Aldrich, St. Louis, 
MO, USA 
3-isobutyl-1-methyl-
xanthine (IBMX) 
Cyclic nucleotide 
phosphodiesterase inhibitor 
Sigma-Aldrich, St. Louis, 
MO, USA 
Ionomycin (from 
Streptomyces conglobatus) 
Ca
2+
 ionophore for AA/2-
AG assay 
Calbiochem, La Jolla, CA, 
USA 
Isoproterenol -adrenoceptor agonist for 
adenylyl cyclase assay 
Sigma-Aldrich, St. Louis, 
MO, USA 
Orexin-A 
(human/bovine/rat/ mouse) 
Orexin receptor agonist PolyPeptide Laboratories 
Group, Strasbourg, France 
Pertussis toxin (PTx) Gαi inhibitor for adenylyl 
cyclase assay 
Sigma-Aldrich, St. Louis, 
MO, USA 
Phosphatidylbutanol 
(PdtBut) 
Standard for TLC 
separation 
BIOMOL by Enzo Life 
Sciences, Plymouth 
Meeting, PA, USA 
Thapsigargin Stimulant of Ca
2+
 release 
and influx for AA/2-AG 
assay 
Sigma RBI, Natick, MA, 
USA 
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12-O-tetradecanoyl-
phorbol-13-acetate (TPA) 
Protein kinase C stimulant 
for PLD assay 
Sigma-Aldrich, St. Louis, 
MO, USA 
 
 
3.4 Phospholipase D Assay 
 
The method used was based on that described by Jäntti et al. (2012) with some 
modifications. The transphosphatidylation assay enables specific measurement of PLD 
activity by providing primary alcohols (here 1-butanol), the preferred substrate of PLDs, 
to be utilized instead of water for the hydrolysis reaction (reviewed Morris et al., 1997). 
This has the advantage over the normal PA-producing pathway, as PA can be generated 
in multiple ways and therefore does not solely indicate PLD activity. Production of 
phosphatidylbutanol (PdtBut) was thus used as the indicator of PLD activity. Cells were 
plated on 6-well plates (Cellstar) at 150 000 cells/well (C3H10T1/2, HIB1b) or 200 000 
cells/well (CHO-hOX1) one day prior to labelling. For OX1 overexpression, cells were 
transduced with bac410-OX1-GFP baculovirus (described below) for 5 h prior to 
labelling.  
 
Cells were labelled with 0.02 μCi/mL [14C]-palmitic acid (Perkin Elmer, Boston, MA, 
USA) in cell culture medium overnight for approximately 18 h. The labelling medium 
was then removed and replaced with normal cell culture medium, in which the cells 
were allowed to settle for 1 h. The cells were activated in cell culture medium + 0.3% 1-
butanol with the activation treatments (Table 2) for 30 min at 37°C. The activation 
medium was then removed, the cells washed once with PBS, and replaced with 300 μL 
ice-cold methanol. While keeping the plates on ice, the cells were scraped from the 
wells and collected to 2 mL Eppendorf tubes. The wells were then washed with another 
300 μL methanol and collected and combined with the first samples. 
 
For lipid extraction, 500 μL of chloroform was added to the Eppendorf tubes and the 
samples mixed by vortexing, then incubated for 15 min at room temperature. Next, 400 
μL of water was added and the samples mixed by vortexing. The samples were then 
centrifuged (5 min, 10 000 rpm), after which the upper phase was removed and the 
lower phase (containing the lipids) was dried under a stream of nitrogen gas. The lipids 
were dissolved in chloroform:methanol (19:1) and 3 μL of cold PtdBut standard added 
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to some of the samples. The samples were loaded onto thin layer chromatography 
(TLC) plates (Silicagel 60, Merck, Darmstadt, Germany) pretreated with 1% K
+
-oxalate 
in methanol:water (2:3) and oven dried at 110°C for at least 1 h. The plates were 
developed using the upper phase of ethylacetate:isooctane:acetic acid:water 
(110:50:20:100) in an unlined chromatography tank. 
 
3.5 AA and 2-AG Release Assay 
 
The methods used were based on those described by Turunen et al. (2012) with some 
modifications. Production of 2-AG indicates DAGL activity whereas AA may be 
released via multiple pathways, including phospholipase A2 (cPLA2) activity and 2-AG 
breakdown. Cells were plated on 6-well plates (Cellstar) at 150 000 cells/well 
(C3H10T1/2, HIB1b) or 200 000 cells/well (CHO-hOX1) one day prior to labelling. For 
OX1 overexpression, cells were transduced with bac410-OX1-GFP baculovirus 
(described below) for 5 h prior to labelling.  
 
Cells were labelled with 0.3 µCi/mL [
14
C]-AA (Perkin Elmer, Boston, MA, USA) in 
cell culture medium overnight for approximately 18 h. The labelling medium was then 
removed and cells washed twice with Na
+
-Elliot (Appendix 1) + 10 mM glucose, 1 mM 
CaCl2, 0.1% lipid-free bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO, 
USA). The cells were then activated in this same buffer with the activators (Table 2) for 
7 min at 37ºC, after which the supernatant was collected to Eppendorf tubes.  
 
For lipid extraction, the samples were centrifuged (1 min, 16 000 rpm) to remove 
detached cells and 800 µL of the supernatant transferred to Kimax tubes (Kimble Glass 
Inc., Vineland, NJ, USA). Then 2 mL methanol and 1 mL chloroform was added to the 
tubes and mixed by vortexing, followed by 1 mL water and 1 mL chloroform and mixed 
again by vortexing. The tubes were centrifuged (5 min, 500 rpm) and the lower phase 
transferred to 2 mL Eppendorf tubes and dried under a stream of nitrogen gas. The 
lipids were dissolved in chloroform:methanol (19:1) and loaded on to TLC plates 
(Silicagel 60, Merck, Darmstadt, Germany) previously oven dried at 110ºC for at least 
one hour, along with the AA and 2-AG standards. The plates were developed using 
ethylacetate:isooctane:acetic acid (144:56:20) in a chromatography tank lined with filter 
paper. 
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3.6 Baculovirus Vector and Transduction 
 
Generation of the baculovirus expression vector for human C-terminally green 
fluorescent protein (GFP) tagged OX1 receptor (OX1-GFP) under cytomegalovirus 
promoter was previously described (Näsman et al., 2006). The virus stocks were grown 
and maintained in Sf9 insect cells by Jaana Putula (Department of Veterinary 
Biosciences, University of Helsinki, Helsinki, Finland). For use with C3H10T1/2 and 
HIB1b cells, 500 μL virus stock/well was centrifuged (30 min, 16 000 rpm) and the 
virus pellet re-suspended in 1 mL/well of cell culture medium before adding to the cells. 
Successful transduction was confirmed via fluorescent microscopy to check the 
presence of GFP within the cells. 
 
3.7 TLC Quantification 
 
In both the PLD and AA/2-AG assays, TLC plates were allowed to dry and then 
exposed overnight with an imaging plate (Fujifilm, Tokyo, Japan). The imaging plate 
was scanned with the Fujifilm Fluor-Imager FLA-5100 (Fujifilm, Tokyo, Japan). The 
TLC plates were placed in an iodine vapour tank to allow visualization of the standards. 
After marking the desired bands, the plates were then scanned into the computer to 
allow for image scaling and overlay of the standards with the radioactivity images. Band 
mean intensities and areas were measured with Nikon Imaging Software NIS-Elements 
AR (Version 3.1, Nikon, Tokyo, Japan) and background level intensity subtracted. 
 
3.8 Adenylyl Cyclase Assay 
 
Cells were plated on 24-well plates (Cellstar), pretreated with 0.5% polyethyleneimine, 
at 30 000 cells/well (C3H10T1/2, HIB1b, CHO-hOX1) two days prior to the 
experiment. Production of cAMP was used as the indicator of adenylyl cyclase activity. 
For PTx and CTx treatments the cells were incubated overnight with the toxin for 
approximately 18 h.  
 
The cells were labelled with 5 µCi/mL [
3
H]-adenine (Perkin Elmer, Boston, MA, USA) 
in cell culture medium for 2 h. Inhibitor and activator solutions were prepared in Na
+
-
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Elliot. The labelling medium was removed and 200 µL Na
+
-Elliot + 0.5 mM IBMX 
inhibitor solution (Table 2) added and cells incubated for 10 min at 37ºC. The inhibitor 
solution was then replaced with 200 µL activation solution containing the activators 
(Table 2) and cells incubated for 20 min at 37ºC. Following the incubation the 
supernatant was discarded and 200 µL ice-cold 0.33 M perchloric acid (PCA) added and 
the cells frozen immediately. 
 
The samples were thawed at room temperature and then centrifuged to remove the 
precipitate (10 min, 2500 rpm). The ATP+ADP and cAMP fractions were separated and 
collected using sequential Dowex/Alumina chromatography (Holmqvist et al., 2005). 
Cells were first centrifuged (10 min, 2500 rpm) to remove the precipitate. Then equal 
amounts of supernatants were added to the Dowex columns along with 0.33 M PCA to 
obtain a total volume of 1 mL. The ADP + ATP fractions were eluted with 2 mL water 
into large scintillation vials. The Dowex columns were then placed on top of the 
Alumina columns and the samples eluted into Alumina with 10 mL water. The cAMP 
fractions were then eluted with 4 mL 0.1 M imidazole into large scintillation vials. To 
each vial scintillation cocktail (HiSafe 3, Wallac-PerkinElmer, Turku, Finland) was 
added and the radioactivity measured with Wallac 1414 liquid scintillation counter 
(Wallac-PerkinElmer, Turku, Finland). The amount of [
3
H]-cAMP was calculated as a 
percentage of the total eluted [
3
H]-ATP + [
3
H]-ADP.  
 
3.9 Data Analysis 
 
All data have been presented as the mean ± standard error; n refers to the number of 
batches of cells. Each experiment was run in duplicate (Western Blot, PLD, AA, and 2-
AG) or quadruplicate (cAMP) at least three times. The data presented is a summary of 
the data sets generated by each batch of cells, unless specifically indicated to be from a 
single representative experiment. The data were normalized to basal or standard stimuli 
to allow comparison and averaging of different data sets (see figure legends). Student's 
paired or non-paired t-test with Bonferroni correction for multiple comparisons was 
used for all comparisons, utilizing Microsoft Excel. 
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4 Results 
 
4.1 Label Uptake 
 
The efficiency of the cells to take up the radio-labelled tracers was tested before their 
use in further experiments. In all cases all cell lines showed effective cellular uptake of 
the labels, with efficiencies ranging from 72.1 – 89.8%.  
 
4.2 p38 Western Blot Analysis 
 
Different concentrations of orexin-A were tested, along with different activation time 
points to determine the best conditions for kinase activation. Sucrose, cyclohexamide 
(CHX), and 10% FCS (functions described in Table 2) were tested as positive controls, 
again with different time points. Sucrose and CHX produced no response from either 
cell line, while 10% FCS gave decent activation in C3H10T1/2 cells but not in HIB1b 
cells. Weak activation of p38 MAPK was observed with both 100 nM and 1 µM orexin-
A concentrations after a 10 min activation period, and stronger activation after a 30 min 
activation period in C3H10T1/2 cells (Figure 9). No significant activation above the 
basal levels was observed with any concentration of orexin-A at either time point in 
HIB1b cells (Figure 9). The p38 assay was only performed once, since it was essentially 
only a control for cell function and reproduced the results of the previous study by 
Sellayah et al. (2011).  
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Figure 9. Western blot analysis of phosphorylated (active) p38 mitogen activated 
protein kinase (MAPK) and total extracellular signal-regulated kinase (ERK) (as a 
loading control). (A) Infrared image as captured by Odyssey Infrared Imager and 
software (LI-COR Inc.). C = C3H10T1/2 cells; H = HIB1b cells. (B) Activation of p38 
MAPK normalized to the total ERK present in the cells. Image and data from one 
representative experiment; error bars represent standard deviation between two 
replicates. 
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4.3 Phospholipase D Assay 
 
CHO-hOX1 cells were tested in parallel with the C3H10T1/2 and HIB1b cells. The 
responses to the control and orexin treatments in CHO-hOX1 cells were consistently as 
expected and had been previously reported (Jäntti et al., 2011) with strong activation of 
PLD by the both the positive control TPA and orexin-A (not shown), confirming no 
technical problems with the assay.  
 
TPA stimulation in C3H10T1/2 and HIB1b cells resulted in clear activation of PLD, as 
can be seen from the dark PtdBut bands on the TLC plate, whereas orexin-A (1 nM  1 
µM) yielded no visible PtdBut bands (Figure 10). 
 
 
 
Figure 10. TLC separation of the [
14
C]-palmitic acid containing molecules produced 
upon stimulation. Phosphatidylbutanol (PtdBut) is indicative of phospholipase D 
activity. Radioactivity image as captured by an imaging plate from TLC plate; image 
from one representative experiment. C = C3H10T1/2 cells; H = HIB1b cells. 
 
 
After measuring the mean band intensity, the data was normalized to TPA by setting the 
TPA response to 100%. TPA was chosen rather than the basal controls because the 
orexin-stimulated responses were so low, nearly the same as basal levels, therefore any 
small variation may have been perceived as larger than in reality if compared to the 
basal. TPA gave a consistent response across all the cell lines and experiments. It is 
clear from Figure 11 that orexin-A produced no significant activation of PLD in either 
C3H10T1/2 or HIB1b cells.  
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Figure 11. Effect of orexin stimulation on phospholipase D activity, as measured by 
phosphatidylbutanol (PtdBut) production. Data was normalized to the positive control 
TPA. Comparisons are to the basal controls. Error bars indicate standard error of the 
mean (n = 34); ns, not significant (P > 0.05); ***P < 0.001. 
 
 
Following transduction of the cells to overexpress OX1 receptors, HIB1b cells showed a 
marked increase in PLD activity upon stimulation with orexin-A (Figure 12). This 
demonstrates that orexin-induced PLD activation is at least possible in these cells, 
although it appears to not be a commonly used pathway in their native state. 
C3H10T1/2 cells did not show a significant difference in orexin-induced PLD activation 
between normal and transduced cells (Figure 12). However, C3H10T1/2 cells seemed to 
have more difficulty in taking up the virus, as assessed based on the GFP fluorescence 
using a fluorescence microscope (not shown). Various virus concentrations and 
incubation time periods were tried, and still these cells did not respond well to the 
transduction. Thus it is more probable that the lack of response is due to inefficient 
transduction or recombinant expression and the subsequent lack of OX1 receptor 
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overexpression, rather than an incapability of OX1 receptors to couple to PLD activation 
in these cells. 
 
 
 
Figure 12. Effect of orexin stimulation on phospholipase D activity in cells 
overexpressing OX1 receptors, as measured by phosphatidylbutanol (PtdBut) 
production. Data is presented as the mean relative optical intensity of the bands of 
interest. Representative data from a single experiment; error bars show standard 
deviation between two replicates.  
 
 
4.4 AA and 2-AG Release Assay 
 
CHO-hOX1 cells were tested in parallel with the C3H10T1/2 and HIB1b cells. CHO-
hOX1 cells responded to orexin-A treatments with increased AA and 2-AG release in a 
concentration-dependent manner (not shown) which for the most part was consistent 
with the results previously published (Turunen et al., 2012). There was however some 
variation in the responses between experiments, raising potential concern over the 
efficacy of the assay.  
 
40 
 
Difficulties arose in identifying a strong positive control for this assay and no strong 
bands were observable on the TLC plates from any of the treatments, except for the AA 
band upon ionomycin treatment in C3H10T1/2 cells (Figure 13). Ionomycin was 
initially chosen as it stimulated release of both AA and 2-AG in the CHO-hOX1 control 
cells. In C3H10T1/2 cells, ionomycin produced significant AA release, but not in 
HIB1b cells (Figure 14). For 2-AG release, the responses to ionomycin were not 
significant in either cell line (Figure 15). Other positive controls tested were 
thapsigargin and ATP (not shown). All drug functions are described in Table 2.  
 
 
 
Figure 13. TLC separation of the [
14
C]-AA lipid species arachidonic acid (AA) and 2-
arachidonoyl glycerol (2-AG) released upon stimulation. Radioactivity image as 
captured by an imaging plate from TLC plate; images from one representative 
experiment. (A) C3H10T1/2 cells; (B) HIB1b cells.  
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Figure 14. Effect of orexin stimulation on arachidonic acid release. Data was 
normalized to the basal controls. Comparisons are to the basal controls. Error bars 
indicate standard error of the mean (n = 34); ns, not significant (P > 0.05); *P < 0.05; 
**P < 0.01. 
 
 
Orexin-A stimulation produced no significant change in AA release in C3H10T1/2 
cells; in HIB1b cells, orexin-A significantly decreased AA release (Figure 14).  
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Figure 15. Effect of orexin stimulation on 2-arachidonoyl glycerol release. Data was 
normalized to the basal controls. Comparisons are to the basal controls. Error bars 
indicate standard error of the mean (n = 34); ns, not significant (P > 0.05). 
 
 
The responses to orexin-A were not significant in either C3H10T1/2 or HIB1b cells 
when measuring 2-AG release (Figure 15). 
 
When cells were transduced to overexpress OX1 receptors, HIB1b cells displayed an 
increase in both AA and 2-AG release in response to orexin-A (Figures 16 & 17), 
demonstrating these pathways are capable of being activated by orexin in these cells. 
C3H10T1/2 cells did not show a change in AA or 2-AG release (Figures 16 & 17). As 
discussed above (4.3 Phospholipase D Assay) this may be due to low virus uptake or 
protein production from the virus in C3H10T1/2 cells. Therefore the same conclusion 
holds true, that it is probably a lack of successful transduction yielding this non-
response rather than an inability of the OX1 receptors to trigger AA and 2-AG release in 
these cells. 
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Figure 16. Effect of orexin stimulation on arachidonic acid release in cells 
overexpressing OX1 receptors. Data is presented as the mean relative optical intensity of 
the bands of interest. Representative data from a single experiment; error bars show 
standard deviation between two replicates.  
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Figure 17. Effect of orexin stimulation on 2-arachidonoyl glycerol release in cells 
overexpressing OX1 receptors. Data is presented as the mean relative optical intensity of 
the bands of interest. Representative data from a single experiment; error bars show 
standard deviation between two replicates.  
 
 
4.5 Adenylyl Cyclase Assay 
 
Treatment with forskolin significantly increased cAMP production in both C3H10T1/2 
and HIB1b cells (Figure 18), confirming the presence of adenylyl cyclase in these cells 
and the feasibility of this assay. Isoproterenol, a known stimulator of the Gαs-coupled β-
adrenergic receptors, also stimulated adenylyl cyclase activation in both cell lines 
(Figure 19), with the response being especially strong in C3H10T1/2 cells. CHO-hOX1 
cells were tested in parallel to confirm the assay was working correctly; increased 
cAMP production was observed with both forskolin and orexin-A in these cells (not 
shown). In C3H10T1/2 and HIB1b cells, orexin-A treatments did not affect basal cAMP 
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production, even at concentrations as high as 1 μM, indicating that OX1 receptors do not 
readily couple to Gαs in these cells (not shown).  
 
 
 
Figure 18. Activation of adenylyl cyclase by forskolin, as measured by cAMP 
production. Data was normalized to total ATP + ADP levels. Comparisons are to the 
basal controls. Error bars indicate standard error of the mean (n = 67); ***P < 0.001.  
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Figure 19. Effect of isoproterenol stimulation on adenylyl cyclase activity, as measured 
by cAMP production. Data was normalized to total ATP + ADP levels. Representative 
data from a single experiment; error bars show standard deviation between four 
replicates.  
 
 
In order to further investigate this response, treatments of constant forskolin 
concentrations combined with various orexin-A concentrations were applied to the cells. 
In C3H10T1/2 cells, the result of these experiments was a biphasic curve, with 
increasing cAMP production at lower orexin-A concentrations and reduced cAMP 
production at higher orexin-A concentrations (Figure 20). Based on these results it 
would seem there is coupling of the OX1 receptors to both Gαs, producing the 
stimulatory effect, and to Gαi, producing the inhibitory effect, and that this 
determination may be concentration-dependent. However, it must be noted that also 
other cascades can be involved (see 1.4.5 Influence on Adenylyl Cyclase). In HIB1b 
cells, no change was observed in cAMP production with any concentration of orexin-A 
(Figure 20).  
 
 
47 
 
 
Figure 20. Effect of orexin stimulation on adenylyl cyclase activity, as measured by 
cAMP production. Data was normalized to total ATP + ADP levels. Representative data 
from a single experiment; error bars show standard deviation between four replicates.  
 
 
CTx and PTx were used in an attempt to sort out the stimulatory and inhibitory effects 
(data not shown). The results were somewhat contradictory however, and due to time 
constraints further investigations were not carried out.  
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5 Discussion 
 
5.1 Signalling Responses to Orexin Differ From Those Observed in Recombinant 
Cells 
 
The successful activation of p38 MAPK in C3H10T1/2 cells confirmed the presence of 
functional orexin receptors and replicated the previous results obtained by Sellayah et 
al. (2011). As already discussed in the introduction (1.2.3 Orexins and Brown Adipose 
Tissue) the activation of p38 MAPK is necessary for these cells to differentiate into 
mature brown adipocytes. Orexin-induced activation of p38 MAPK has also been 
previously demonstrated in recombinant CHO-hOX1 cells, where it is required for 
induction of cell death (Ammoun & Lindholm et al., 2006). 
 
The lack of p38 MAPK activation in HIB1b cells is concerning. However, activation 
had not been demonstrated previously in the HIB1b cell line and thus is potentially not a 
critical pathway in these cells. The alternative explanation is a lack of functional OX1 
receptor expression at the cell membrane. If this explanation is accepted, it would of 
course impact the rest of the studies carried out and could serve as a possible 
explanation for the severe lack of any response observed in HIB1b cells in any of the 
assays. However, orexin responses in this cell line are seen in the studies by Sellayah et 
al. (2011).  
 
Failure of orexin to stimulate PLD activation in C3H10T1/2 and HIB1b cells was 
surprising, since there was such a strong response in the recombinant CHO-hOX1 cells 
in previously published results (Jäntti et al., 2011) and our control CHO-hOX1 cells. It 
was noted that orexin also failed to activate PLC in C3H10T1/2 and HIB1b cells 
(Putula, unpublished results); however this should not have a major impact on PLD as it 
was already demonstrated that orexin acts independently of PLC through PKCδ to 
activate PLD (Jäntti et al., 2011). Granted, these results were obtained with the 
recombinant cells and thus again the signalling could be operating differently in the 
BAT precursor cells. AA has also been linked to PKC activation (Shirai et al., 1998; 
Cho & Stahelin, 2006), which could be another explanation for the lack of PLD 
activation, based on the lack of orexin-induced AA release observed in the C3H10T1/2 
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and HIB1b cells. However, AA was deemed not required for PLD activation in the 
recombinant cells (Jäntti et al., 2011). The data from the OX1 overexpression 
transduction of these cells indicates that HIB1b cells are at least capable of orexin-
induced PLD activation, even if it may not be a normally significant pathway. The 
physiological significance of PLD activation in relation to orexins remains unknown, 
and therefore it is difficult to speculate as to why these BAT precursor cells would not 
have the same response as the recombinant cells. 
 
The results gathered from the AA/2-AG release assay indicate no increases in release of 
either molecule in response to orexin in C3H10T1/2 or HIB1b cells, a result which is 
again in opposition to the previously available data from recombinant CHO-hOX1 cells; 
HIB1b cells even showed a significant decrease in AA release upon orexin treatment. In 
the recombinant cells orexin stimulated an increase in release of both AA and 2-AG, 
resulting from the activation of the cPLA2 and DAGL signalling cascades (Turunen et 
al., 2012). Thus once again it appears the targets of orexin signalling and cellular 
responses differ in the BAT precursor cells when compared to the recombinant cells. In 
this case however it is not so clear if the difference is entirely based on different 
signalling in these cells or if some part can be attributed to technical obstacles operating 
at the level of the assay itself. The high basal levels made sorting out true responses 
difficult, as did a lack of any consistent strong positive control across the cell lines. 
There was also some variation of the responses observed in the control CHO-hOX1 
cells. If we assume however that the differences observed are truly different cellular 
responses, perhaps it makes sense that AA and 2-AG release are not so important in 
BAT precursor cells. Brown adipose tissue acts as a defense mechanism against weight 
gain, where as AA content in adipose tissue has been associated with obesity in humans 
(Savva et al., 2004). In terms of differentiation, Peterson et al. (2003) demonstrated that 
AA inhibits the differentiation of 3T3-L1 preadipocytes to adipocytes. This may also be 
true then for the C3H10T1/2 and HIB1b precursor cells, and we should not expect to see 
AA increases then if orexin is triggering differentiation to brown adipocytes. 
Endocannabinoids such as 2-AG have been strongly linked to adipose tissue, adipocyte 
growth and differentiation, and overall energy balance (Pagano et al., 2008; Uberto, 
2008). Increased 2-AG and overactivation of the endocannabinoid system are associated 
with obesity, and treatment of brown adipocytes with endocannabinoid receptor 
agonists decreases the expression of UCP1 (Jbilo et al., 2005; Perwitz et al., 2006), a 
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protein whose increased expression is one of the hallmarks of BAT; conversely 
endocannabinoid receptor antagonists reverse diet-induced weight gain by increasing 
energy expenditure and BAT function (Jbilo et al., 2005), and possibly induce 
transdifferentiation of WAT to BAT (Uberto, 2008). Extrapolating these observations to 
the C3H10T1/2 and HIB1b cells, again perhaps it makes sense that orexin does not 
stimulate an increase in 2-AG release. When looking at the upstream activity, AA and 
2-AG release could be partially influenced by PLD and PLC activity. Since neither of 
these enzymes was activated by orexin in the BAT precursor cells, it would follow then 
that the downstream release of AA and 2-AG would also be impaired.  
 
The adenylyl cyclase assay yielded some novel positive results. While orexin itself did 
not produce noticeable changes in cAMP production, when combined with forskolin (a 
strong activator of adenylyl cyclase) it became apparent that orexin may trigger both 
stimulatory and inhibitory effects on adenylyl cyclase. This was suggested due to the 
biphasic nature of the curve observed, which was reminiscent (although opposite) to the 
curve observed in CHO-hOX1 cells upon orexin stimulation (Holmqvist et al., 2005). It 
has already been noted that the response of adenylyl cyclase to orexin is rather complex, 
as discussed in the introduction (1.4.5 Influence on Adenylyl Cyclase). The capability 
of GPCRs to couple to multiple G-proteins is well documented and provides a challenge 
when trying to determine specific receptor responses (reviewed in Kukkonen, 2004). 
GPCRs can assume multiple active forms, each of which interact differently with the 
associated G-proteins; a phenomenon termed stimulus trafficking describes how the 
ligands themselves can promote specific active conformations (reviewed in Kukkonen, 
2004). The multiple isoforms of adenylyl cyclase in existence, each of which respond 
and are regulated independently, are another source of variation complicating the 
determination of specific receptor-triggered effects (Patel et al., 2001).  
 
CTx and PTx can be used to separate some inhibitory and stimulatory effects on 
adenylyl cyclase. CTx catalyzes ADP-ribosylation of Gαs thereby eliminating its 
capability to hydrolyze GTP  GDP + Pi. This locks Gαs in the GTP-bound active 
form, causing continual activation of adenylyl cyclase (Sanchez & Holmgren, 2011). 
Therefore, the treatments on cells previously treated with CTx should show only 
inhibitory effects, assuming that adenylyl cyclase is saturated with Gαs. PTx catalyzes 
ADP-ribosylation of Gαi which prevents it from interacting with GPCRs at the 
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membrane and thus prevents its ability to inhibit adenylyl cyclase (Burns, 1988). 
Therefore, the treatments on cells previously treated with PTx should show only 
stimulatory effects. Unfortunately, the studies with CTx and PTx did not bring a clearer 
understanding of these inhibitory and stimulatory components of the orexin response. 
Due to time constraints further investigation was not possible within the scope of this 
thesis, thus this area will be a target for future studies.  
 
As for the physiological relevance of adenylyl cyclase activity, the expression of UCP1 
in BAT and subsequent onset of thermogenesis is dependent upon increased cellular 
cAMP levels (Lafontan & Berlan, 1993). cAMP is a well known activator of PKA as 
well as other kinases; in the case of BAT increased cAMP can activate p38 MAPK, 
which plays a major role in regulating transcription of the UCP1 gene (Cao et al., 2004) 
and initiating differentiation to mature brown adipocytes (Cao et al., 2001; Cao et al., 
2004; Sellayah et al., 2011). 
 
 
5.2 Limitations and Sources of Error 
 
General sources of error for all of the experiments can arise from the cell culture phase. 
Accurate cell counting and splitting of cells are necessary to ensure comparable 
concentrations. Cell growth and confluency had to be carefully monitored, as it was 
noted that both C3H10T1/2 and HIB1b cells have a tendency for spontaneous 
differentiation if they become too confluent. Differentiation would of course change the 
cells’ properties and subsequently affect signalling and responses to the treatments. 
During the sample preparation and treatment incubations the cells had to be handled 
gently as to not induce activation by any physical force. 
 
One problem encountered with the western blot analysis was bleed-through of signal 
between the two infrared channels. This became an issue because of the very close 
proximity of the bands from the total ERK control and the phospho-p38 MAPK bands, 
due to their similar size. It would have been nice to have a different baseline control that 
was further away from the phospho-p38 MAPK, however total ERK gave a consistent 
and clear signal and was convenient for normalizing the data. Thus as long as care was 
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taken when adjusting the parameters for scanning and measuring the band intensity, it 
was acceptable to continue using total ERK as the baseline control. 
 
Potential limitations of the PLD and AA/2-AG assays lie in the extraction efficiency of 
the lipids from the lysed cells/supernatant. Sources of error can also be found in the 
assessment of the bands and targeting the area for measurement of band intensity. 
Additionally, it is not possible to assign a specific source to the AA/2-AG produced, as 
these molecules can be produced via multiple pathways (see 1.4.4 Generation of Lipid 
Messengers). Therefore it also holds that a lack of AA/2-AG release could be a result of 
a number of different upstream enzymes not being activated.  
 
A source of variation specific to the adenylyl cyclase assay would be in the composition 
of the columns. Any dirt or contamination on the columns will affect the run-through or 
binding of the molecules and therefore the separation and final concentrations available 
for measuring. In addition, direct assumptions of coupling to Gαs and Gαi made from 
cAMP concentration measurements carry an innate risk as cAMP levels may also be 
regulated in other ways, however use of the inhibitor solution should prevent this. 
 
 
5.3 Future Directions 
 
It is clear from the results presented here that orexin signalling does not behave the 
same in all cell/tissue types, and between native and recombinant receptor expression. 
This suggests a need for further studies in cell lines of different origin with native 
orexin receptor expression. The identification of such cells will lead to more 
possibilities to study the effects of orexin at the cellular level, and can hopefully lead to 
a better understanding of the physiological significance of the various cellular responses 
observed. This will also help to unravel a better overall picture of the role for orexins, 
and potentially open up new therapeutic opportunities targeted at the various aspects of 
orexin signalling. 
 
In terms of BAT, the next logical experiments would be to continue with the adenylyl 
cyclase assays to confirm the dynamics of the seemingly stimulatory and inhibitory 
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effects of orexin on that pathway, and secondly, to assess the role of cAMP in the BAT 
differentiation. 
 
6 Conclusions 
 
This study originated with the goal of examining orexin signalling in two mouse BAT 
precursor cell lines with native OX1 receptor expression, to gain insight into the cellular 
responses induced by orexin and compare to the responses previously shown in 
recombinant cells. It was expected that the cellular responses to orexin in C3H10T1/2 
and HIB1b cells would be the same or similar to those observed previously in CHO 
cells recombinantly expressing the OX1 receptors. This was not the case however. 
Taken altogether, the results of this thesis indicate that responses to orexin signalling in 
the BAT precursor cells are not the same as when orexin receptors are recombinantly 
expressed, nor are they necessarily the same even between the two BAT precursor cell 
lines. This raises interesting questions regarding the variability of responses to orexin in 
different tissue types, and demonstrates the importance of finding more cell lines which 
natively express orexin receptors. Studying the cellular responses to orexin and 
determining the physiological significance of these responses in specific tissue types or 
cell lines will lead to a better overall understanding of orexin signalling and potentially 
reveal new therapeutic applications for orexin-related disorders. Additionally, it may be 
possible through such studies to determine the factors leading to tissue-specific 
signalling of GPCRs. 
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9 Appendix 1. Solutions 
 
9.1 Lysis Buffer for Western Blot Analysis, pH 7.5 
 
TKB buffer* desired volume 
phosSTOP 1:10 
protease inhibitor 1:100 
PMSF 1:100 
 
*TKB buffer = 50 mM HEPES, 150 mM NaCl (pH 7.5) + 10% (v/v) glycerol, 1% (v/v) 
Triton X-100, 1.5 mM MgCl2, 1 mM EDTA, 10 mM Na
+
-pyrophosphate, 1 mM Na
+
- 
orthovanadate, 10 mM NaF, 250 μM p-nitrophenol phosphate 
 
phosSTOP phosphatase inhibitor cocktail (Roche, Mannheim, Germany) 
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) 
PMSF, phenylmethylsulfonylfluoride 
 
9.2 Gel Recipe used in SDS-PAGE (1 gel) 
 
Lower Gel, 10%: 
40% acrylamide 1.25 mL 
H2O 2.5 mL 
1.5 M Tris-HCl buffer, pH 8.8 1.25 mL 
10% SDS 50 μL 
10% APS 50 μL 
TEMED 2 μL 
 
APS, ammonium persulfate 
TEMED, N,N,N′,N′-tetramethylethane-1,2-diamine 
 
Upper Gel, 5%: 
40% acrylamide 250 μL 
1M Tris-HCl buffer, pH 6.8 256 μL 
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H2O 1.5 mL 
10% SDS 21 μL 
10% APS 21 μL 
TEMED 2 μL 
 
9.3 Tris-Buffered Saline (TBS) Recipe (10X), pH 7.6 
 
Tris base 20 mM 
NaCl 137 mM 
 
Adjust the pH with a strong HCl solution.  
Add H2O to 1000 mL final volume. 
 
9.4 Na
+
-Elliot Buffer Recipe (10X), pH 7.4 
 
NaCl 1370 mM 
KCl 50 mM 
MgCl2·6H2O 12 mM 
NaHCO3 42 mM 
KH2PO4 4.4 mM 
HEPES 200 mM 
 
Add H2O to 1000 mL final volume.  
Add 1 mM CaCl2 and 10 mM glucose from 1 M stock solutions when used. 
 
